BC Innovations | Nov 13, 2018
Distillery Therapeutics


INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...
BC Week In Review | Jul 7, 2017
Company News

Arrien out-licenses RORgammaT series and autoimmune candidate ARN-6039

Arrien Pharmaceuticals LLC (Salt Lake City, Utah) granted an undisclosed pharmaceutical company worldwide rights to ARN-6039 and a series of compounds targeting RAR-related orphan receptor C thymus-specific isoform ( RORgamma2 ; RORgammaT). Arrien said the target...
BC Week In Review | Jun 13, 2016
Clinical News

ARN-6039: Phase I started

Arrien began a 1-year, double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of oral ARN-6039 in about 50 healthy volunteers. Arrien Pharmaceuticals LLC , Salt Lake City, Utah   Product: ARN-6039   Business:...
Items per page:
1 - 3 of 3